120 related articles for article (PubMed ID: 38666355)
1. α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.
Levin J; Baiardi S; Quadalti C; Rossi M; Mammana A; Vöglein J; Bernhardt A; Perrin RJ; Jucker M; Preische O; Hofmann A; Höglinger GU; Cairns NJ; Franklin EE; Chrem P; Cruchaga C; Berman SB; Chhatwal JP; Daniels A; Day GS; Ryan NS; Goate AM; Gordon BA; Huey ED; Ibanez L; Karch CM; Lee JH; Llibre-Guerra J; Lopera F; Masters CL; Morris JC; Noble JM; Renton AE; Roh JH; Frosch MP; Keene CD; McLean C; Sanchez-Valle R; Schofield PR; Supnet-Bell C; Xiong C; Giese A; Hansson O; Bateman RJ; McDade E; ; Parchi P
Alzheimers Dement; 2024 Jun; 20(6):4351-4365. PubMed ID: 38666355
[TBL] [Abstract][Full Text] [Related]
2. Misfolded α-Synuclein in Autosomal Dominant Alzheimer's Disease.
Fort-Aznar L; Molina-Porcel L; Ramos-Campoy O; Esteller D; Naranjo L; Lladó A; Balasa M; Ruiz-García R; Antonell A; Sánchez-Valle R
J Alzheimers Dis; 2024; 97(3):1091-1096. PubMed ID: 38250774
[TBL] [Abstract][Full Text] [Related]
3. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
[TBL] [Abstract][Full Text] [Related]
4. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden.
Bentivenga GM; Mammana A; Baiardi S; Rossi M; Ticca A; Magliocchetti F; Mastrangelo A; Poleggi A; Ladogana A; Capellari S; Parchi P
Acta Neuropathol; 2024 Jan; 147(1):18. PubMed ID: 38240849
[TBL] [Abstract][Full Text] [Related]
5. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay.
Bellomo G; Toja A; Paolini Paoletti F; Ma Y; Farris CM; Gaetani L; Salvadori N; Chiasserini D; Wojdaƚa AL; Concha-Marambio L; Parnetti L
Alzheimers Dement; 2024 Apr; 20(4):2444-2452. PubMed ID: 38323747
[TBL] [Abstract][Full Text] [Related]
6. APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology.
Jin Y; Li F; Sonoustoun B; Kondru NC; Martens YA; Qiao W; Heckman MG; Ikezu TC; Li Z; Burgess JD; Amerna D; O'Leary J; DeTure MA; Zhao J; McLean PJ; Dickson DW; Ross OA; Bu G; Zhao N
Acta Neuropathol; 2022 Jun; 143(6):641-662. PubMed ID: 35471463
[TBL] [Abstract][Full Text] [Related]
7. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome.
Giannini G; Baiardi S; Dellavalle S; Zenesini C; Cevoli S; Danner N; Jyrkkänen HK; Rossi M; Polischi B; Quadalti C; Stefanini C; Cortelli P; Milletti D; Herukka SK; Palandri G; Leinonen V; Parchi P
Fluids Barriers CNS; 2022 Sep; 19(1):71. PubMed ID: 36071460
[TBL] [Abstract][Full Text] [Related]
9. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function.
Tosun D; Hausle Z; Iwaki H; Thropp P; Lamoureux J; Lee EB; MacLeod K; McEvoy S; Nalls M; Perrin RJ; Saykin AJ; Shaw LM; Singleton AB; Lebovitz R; Weiner MW; Blauwendraat C;
Alzheimers Dement; 2024 May; ():. PubMed ID: 38770829
[TBL] [Abstract][Full Text] [Related]
12. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
[TBL] [Abstract][Full Text] [Related]
13. Lewy body pathology in Alzheimer's disease.
Kotzbauer PT; Trojanowsk JQ; Lee VM
J Mol Neurosci; 2001 Oct; 17(2):225-32. PubMed ID: 11816795
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
Manne S; Kondru N; Hepker M; Jin H; Anantharam V; Lewis M; Huang X; Kanthasamy A; Kanthasamy AG
J Neuroimmune Pharmacol; 2019 Sep; 14(3):423-435. PubMed ID: 30706414
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort.
Samudra N; Fischer DL; Lenio S; Lario Lago A; Ljubenkov PA; Rojas JC; Seeley WW; Spina S; Staffaroni AM; Tablante J; Wekselman F; Lamoureux J; Concha-Marambio L; Grinberg LT; Boxer AL; VandeVrede L
Alzheimers Dement; 2024 May; 20(5):3334-3341. PubMed ID: 38539061
[TBL] [Abstract][Full Text] [Related]
17. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies.
Fujishiro H; Tsuboi Y; Lin WL; Uchikado H; Dickson DW
Acta Neuropathol; 2008 Jul; 116(1):17-24. PubMed ID: 18446351
[TBL] [Abstract][Full Text] [Related]
18. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
[TBL] [Abstract][Full Text] [Related]
19. Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.
Hall S; Orrù CD; Serrano GE; Galasko D; Hughson AG; Groveman BR; Adler CH; Beach TG; Caughey B; Hansson O
Acta Neuropathol Commun; 2022 Jun; 10(1):90. PubMed ID: 35733234
[TBL] [Abstract][Full Text] [Related]
20. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
